Speaker Profile

CEO, Pierian

Mark McDonough is a global technology business executive with 30 years of experience, and he has been CEO of Pierian since November 2020. His personal mission is to impact change in the field of healthcare in a compassionate yet resolute manner, leading by example. Prior to Pierian, Mark has served as President, CEO, and Board member for private companies like Immunis.AI, a pre-commercial liquid biopsy company, where he secured funding and developed a top flight team within six months of hire, and public companies like CombiMatrix, a leader in high complexity reproductive health testing. McDonough served as President, CEO and board member of CombiMatrix from 2012 through 2018, orchestrating its sale to Invitae in November 2017. Under his leadership, CombiMatrix experienced 14 consecutive quarters of record growth. Earlier in his career, he served in various sales leadership roles at high growth diagnostic companies to include Ventana Medical Systems (acquired by Roche) and US LABS (acquired by LabCorp). He is married with three children and is a proud former Naval Officer having served as a Navigator and Communications Officer on the USS FLETCHER (DD 992).

Clinical Dx Showcase:

Pierian partners with clinicians and medical facilities to advance clinical genomics and modernize patient care.

Bringing NGS Oncology Testing Closer to Home
Building an onsite precision medicine program provides faster results, improved care, and greater control over samples and data. Pierian guides you through the entire process and provides advanced interpretation technology to identify actionable variants, delivered in a best-in-class genomics report.

 Session Abstract – PMWC 2022 Silicon Valley

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative